AP318A - Benzofuran derivatives - Google Patents

Benzofuran derivatives Download PDF

Info

Publication number
AP318A
AP318A AP9200389A AP9200389A AP318A AP 318 A AP318 A AP 318A AP 9200389 A AP9200389 A AP 9200389A AP 9200389 A AP9200389 A AP 9200389A AP 318 A AP318 A AP 318A
Authority
AP
ARIPO
Prior art keywords
group
bromo
methyl
imidazole
phenyl
Prior art date
Application number
AP9200389A
Other languages
English (en)
Inventor
Barry Clive Ross
David Middlemiss
David Ian Carter Scopes
Torquil Ian Maclean Jack
Kevin Stuart Cardwell
Michael Dennis Dowle
Duncan Bruce Judd
Stephan Paul Watson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of AP318A publication Critical patent/AP318A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP9200389A 1991-05-16 1992-05-15 Benzofuran derivatives AP318A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919110636A GB9110636D0 (en) 1991-05-16 1991-05-16 Chemical compounds

Publications (1)

Publication Number Publication Date
AP318A true AP318A (en) 1994-02-15

Family

ID=10695121

Family Applications (1)

Application Number Title Priority Date Filing Date
AP9200389A AP318A (en) 1991-05-16 1992-05-15 Benzofuran derivatives

Country Status (21)

Country Link
US (2) US5332831A (no)
EP (1) EP0514198B1 (no)
JP (1) JPH06211846A (no)
KR (1) KR920021541A (no)
AP (1) AP318A (no)
AT (1) ATE169297T1 (no)
AU (2) AU654350B2 (no)
BG (1) BG98216A (no)
CA (1) CA2068766A1 (no)
CZ (1) CZ243093A3 (no)
DE (1) DE69226472D1 (no)
FI (1) FI935036A (no)
GB (1) GB9110636D0 (no)
IL (1) IL101882A0 (no)
IS (1) IS1609B (no)
MX (1) MX9202281A (no)
NO (1) NO921944L (no)
OA (1) OA09841A (no)
SK (1) SK112893A3 (no)
TW (1) TW221998B (no)
WO (1) WO1992020674A1 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9218449D0 (en) 1992-08-29 1992-10-14 Boots Co Plc Therapeutic agents
US5336779A (en) * 1992-10-08 1994-08-09 Nippon Gohsei Kagaku Kogyo Kabushiki Kaisha Method of producing formylimidazoles
US6071931A (en) * 1995-10-06 2000-06-06 Novartis Ag AT1 -receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
ES2189940T3 (es) 1996-02-29 2003-07-16 Novartis Ag Antagonista de receptor at1 para la estimulacion de la apoptosis.
KR100567183B1 (ko) * 1997-11-14 2006-06-13 론자 아게 포르밀이미다졸의제조방법
NZ587909A (en) 1998-12-23 2012-05-25 Novartis Ag Process of making a compressed tablets containing valsartan and microcrystalline cellulose
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
AU6019700A (en) * 1999-07-21 2001-02-05 Takeda Chemical Industries Ltd. Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
JP2004506012A (ja) * 2000-08-17 2004-02-26 グリアテツク・インコーポレイテツド Ｈ３剤としての新規脂環式イミダゾール
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
ES2560247T3 (es) * 2006-05-05 2016-02-18 Dow Global Technologies Llc Complejos de hafnio de ligandos orgánicos heterocíclicos
PT2090570E (pt) 2006-09-05 2011-12-29 Kyowa Hakko Kirin Co Ltd Derivado de imidazole
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
JP5072675B2 (ja) 2007-04-03 2012-11-14 四国化成工業株式会社 ２−ハロイミダゾール化合物の製造方法
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
EA202090205A1 (ru) 2017-07-07 2020-06-02 Бёрингер Ингельхайм Ветмедика Гмбх Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов
CN110256382A (zh) * 2019-06-06 2019-09-20 武汉药明康德新药开发有限公司 一种2-(5-甲基苯并呋喃-2-基)苯甲腈的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028834A1 (en) * 1979-11-12 1981-05-20 Takeda Chemical Industries, Ltd. Imidazole-5-acetic acid derivatives, their production and use
EP0028833A2 (en) * 1979-11-12 1981-05-20 Takeda Chemical Industries, Ltd. Imidazole derivatives, their production and use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1389827A (en) * 1971-07-23 1975-04-09 Fisons Ltd Tetrazolyl benzopyrans
JPS54148788A (en) * 1978-05-15 1979-11-21 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative and its preparation
US4526896A (en) * 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
AU559687B2 (en) * 1981-07-01 1987-03-19 Upjohn Company, The Pyridinyl-and imidazolyl-benzofurane and benzothiophenes
JPS6163671A (ja) * 1984-09-05 1986-04-01 Shionogi & Co Ltd ２，３−ジヒドロベンゾフラン−５−スルホンアミド誘導体および降圧利尿剤
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4916129A (en) * 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
EP0955294B1 (en) * 1989-06-14 2003-09-24 Smithkline Beecham Corporation Imidazolyl-alkenoic acid
WO1991000281A2 (en) * 1989-06-30 1991-01-10 E.I. Du Pont De Nemours And Company Fused-ring aryl substituted imidazoles
WO1991000277A1 (en) * 1989-06-30 1991-01-10 E.I. Du Pont De Nemours And Company Substituted imidazoles
JPH03204875A (ja) * 1989-10-03 1991-09-06 Wakamoto Pharmaceut Co Ltd テトラゾール酢酸誘導体、及び該誘導体を有効成分とするアルドースレダクターゼ阻害剤
CA2027937A1 (en) * 1989-10-25 1991-04-26 Richard M. Keenan Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles
CA2028925A1 (en) * 1989-11-06 1991-05-07 Gerald R. Girard Substituted n-(imidazolyl)alkyl alanine derivatives
GB8927277D0 (en) * 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
US5190942A (en) * 1991-04-22 1993-03-02 E. R. Squibb & Sons, Inc. Benzoxazole and related heterocyclic substituted imidazole and benzimidazole derivatives
MX9202300A (es) * 1991-05-16 1992-11-01 Glaxo Group Ltd Derivados de benzofurano, procedimiento para su preparacion y composicion farmaceutica que los contiene.
DE4140519A1 (de) * 1991-12-09 1993-06-17 Merck Patent Gmbh Benzofurane

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028834A1 (en) * 1979-11-12 1981-05-20 Takeda Chemical Industries, Ltd. Imidazole-5-acetic acid derivatives, their production and use
EP0028833A2 (en) * 1979-11-12 1981-05-20 Takeda Chemical Industries, Ltd. Imidazole derivatives, their production and use

Also Published As

Publication number Publication date
NO921944D0 (no) 1992-05-15
EP0514198A1 (en) 1992-11-19
DE69226472D1 (de) 1998-09-10
FI935036A0 (fi) 1993-11-15
FI935036A (fi) 1993-11-15
WO1992020674A1 (en) 1992-11-26
EP0514198B1 (en) 1998-08-05
IS1609B (is) 1996-10-18
ATE169297T1 (de) 1998-08-15
CA2068766A1 (en) 1992-11-17
NO921944L (no) 1992-11-17
SK112893A3 (en) 1994-11-09
IS3865A (is) 1992-11-17
AU1632192A (en) 1993-03-11
CZ243093A3 (en) 1994-03-16
AU654350B2 (en) 1994-11-03
KR920021541A (ko) 1992-12-18
BG98216A (en) 1994-08-15
GB9110636D0 (en) 1991-07-03
MX9202281A (es) 1992-11-01
US5332831A (en) 1994-07-26
AU1692692A (en) 1992-12-30
US5498722A (en) 1996-03-12
JPH06211846A (ja) 1994-08-02
OA09841A (en) 1994-08-15
IL101882A0 (en) 1992-12-30
TW221998B (no) 1994-04-01

Similar Documents

Publication Publication Date Title
AP318A (en) Benzofuran derivatives
EP0430709A2 (en) Benzthiophen derivatives
NZ236297A (en) Imidazol-1-yl methyl benzofuran derivatives, medicaments, and precursors
EA012431B1 (ru) Производные пиразола, фармацевтические композиции и их применение
NZ237366A (en) 4-(2'-(tetrazolyl (and carboxy and trifluoromethane sulphonamido)(1,1' biphenylyl)-4-ylmethyl) pyrazole derivatives
WO1992016552A1 (en) 1-imidazolgemethyl benzofuran derivatives as inhibitors of angiotensin ii activity
US5374646A (en) Benzofuran derivatives
US5310927A (en) Benzofuran derivatives
US5317023A (en) Benzofuran derivatives
TWI297683B (en) Diazole derivatives
US8895565B2 (en) Heterocyclic compound and use of the same
JPH06503083A (ja) ベンゾフラン及びベンゾチオフェン誘導体
JP5540227B2 (ja) フェニルイミダゾール化合物
TW201602089A (zh) 多環性ｈｅｒｇ活化劑
US5252593A (en) Pyrazole containing benzofuran derivatives and pharmaceutical compositions
IE921565A1 (en) Benzofuran derivatives
NZ242755A (en) Benzofuranyl methyl imidazole derivatives, pharmaceutical compositions
JPH0625250A (ja) チエノ〔３，４−ｄ〕イミダゾール誘導体、その製造法およびそれを含有する循環器官用剤
WO1992020673A1 (en) Antihypotensive benzofuran derivatives with n-linked 1h-imidazolylmethyl-5-carboxamide substituents
JP2003528087A (ja) 抗ウイルス剤としての４−オキソ−１，４−ジヒドロ−３−シンノリンカルボキサミド
WO1994011369A1 (en) ANTIHYPERTENSIVE 5-[(IMIDAZO[4,5-b]PYRIDIN-3-YL)METHYL]BENZOFURAN DERIVATIVES
AP185A (en) Benzofuran derivatives
AP254A (en) C-Linked pyrazole derivatives.
SI9200253A (sl) Derivati benzofurana
NZ242105A (en) Benzofuran derivatives, preparation, intermediates and pharmaceutical